Dialyzable Leukocyte Extract (Transferon™) Administration in Sepsis: Experience from a Single Referral Pediatric Intensive Care Unit

Abstract

Immunomodulatory agents have been proposed as therapeutic candidates to improve outcomes in sepsis. Transferon™, a dialyzable leukocyte extract (DLE), has been supported in Mexico as an immunomodulatory adjuvant in anti-infectious therapy. Here we present a retrospective study describing the experience of a referral pediatric intensive care unit (PICU) with Transferon™ in sepsis. We studied clinical and laboratory data from 123 patients with sepsis (15 in the DLE group and 108 in the control group) that were admitted to PICU during the period between January 2010 and December 2016. Transferon™ DLE use was associated with lower C reactive protein (CRP), increase in total lymphocyte counts (TLC), and decrease in total neutrophil count (TNC) 72 hours after Transferon™ DLE administration. The control group did not present any significant difference in CRP values and had lower TLC after 72 hours of admission. There was no difference in PICU length of stay between control and Transferon™ DLE group. Transferon™ DLE administration was associated with a higher survival rate at the end of PICU stay. This study shows a possible immunomodulatory effect of Transferon™ on pediatric sepsis patients.

Attenuating the Effects of Novel COVID-19 (SARS-CoV-2) Infection-Induced Cytokine Storm and the Implications

“…Thus, TF can potentially combat immune hyper-responsiveness and hyper-inflammatory associated with COVID-19. 165 Though yet to undergo RCT, TF’s use has been proposed as a therapeutic option against COVID-19. 243 However, a 7-week double-blinded study evaluates the effect of TF supplementation in healthy adults against Upper Respiratory Tract Infections caused by Influenza or Rhinovirus.…”

Vaccinal prevention of nodular dermatitis in Hereford cattle (clinical and immunological implications)

“…It transfers the ability to respond to cellular immunity. As for practical purposes, the transfer factor is mostly used for immunocorrection of cellular immunity [1][2][3].…”

Untitled

“…Por último, recientemente se ha publicado un estudio que abarca un seguimiento desde enero del 2010 hasta diciembre del 2016 y evalúa 123 pacientes pediátricos con sepsis (15 tratados con el medicamento estándar más Transferon ® y 108 de forma canónica) (Castrejón et al, 2019), los pacientes tratados con Transferon ® en comparación con el grupo control presentaron una disminución de los niveles de proteína C reactiva, un incremento en la cuenta leucocitaria así como una disminución en la cuenta de neutrófilos, todo ello en las primeras 72 horas posteriores a la hospitalización, debiéndose destacar que el grupo de pacientes tratados con Transferon ® presenta una mayor tasa de sobrevida. Lo anterior respalda el hecho de la seguridad y capacidad inmunomoduladora de la respuesta inflamatoria, donde se pueden observar efectos positivos del uso de este fármaco como adyuvante terapéutico en patologías con un importante componente inflamatorio.…”